

General Information:

Plan Report ID Number: 20231206lig

Developer Name: Lille Group, Inc

Product Name(s): eScribeHOST

Version Number(s): 7

Certified Health IT

Product List (CHPL) ID(s): 15.02.05.3058.LILG.01.01.1.220214

Developer Real World Testing Page URL: <https://www.escribe.com/transparency-esh.html>

Summary of Testing Methods:

Real World Testing was completed by third party testers per the RWT plans established by Lille Group, Inc. and approved by ACB. Testers were given arbitrary time frames to access the app and complete testing in accordance with an on-going testing approach. Testers were given two sets of log on credentials, one with a complete set of permissions to access all required patient data for testing, one without complete permissions to demonstrate inability to access protected information (170.315(b,e)). In addition, testers were given a set of instructions outlining all actions required to test each criterion completely.

Testers reported all results and findings along with screenshots and copies of downloaded files to the third party testing administrator for review and compilation of results. The testing administrator then converted tester's results to rate of success metric in line with the RWT plans.

Summary of Key Findings:

As described in this report, all testing was conducted successfully with zero nonconforming results found. All testing was completed well within the acceptable time frame of 24 working hours outlined in the RWT plans.

The speed at which testing was completed, an average of 20 minutes per test, demonstrates an on-going ease of use of the application and ease of accessing, editing and downloading all required data.

Each criterion was tested by 3 different testers evaluating 3 patient data sets each, as outlined in the RWT plans. Using multiple third party testers to evaluate each criterion demonstrates continuity of results and real-world interoperability.

No non-conformities were discovered during testing. No deviations from the original testing plan were present. All results are within expected range of success.

Standards Updates via SVAP and/or USCDI:

Standard (and version)	USCDI v1
Updated certification criteria and associated product	b1, b2, e1, g9
Health IT Module CHPL ID	15.02.05.3058.LILG.01.01.1.220214
Method Used for standards update	Cures Update
Date of ONC ACB notification	12/21/2022
Date of customer notification (SVAP only)	N/A
Conformance Measure(s)	Rate of Success for: b1, b2, e1, g9
USCDI Updated certification criteria (and USCDI version)	b1, b2, e1, g9 - USCDI v1

Care Setting(s):

Care Setting	Justification
Cardiology Office	EscribeHost is marketed to cardiology practices and has been tested in accordance with our cardiology clientele. The care setting where patient information should be accessed, added, changed and exchanged is in the office among only professionals with appropriate permissions.

Metrics and Outcomes:

All tests are reported in the metric of rate of success. Rate of success is reported as the percentage of successful attempts to perform actions defined above out of total attempts to perform actions defined in RWT plans. All attempts are defined as successful if performed completely and in accordance with all specifications within a reasonable time, defined as one day (24 hours), or one working day (24 hours discounting weekends and holidays) for criteria relying on outside parties who do not operate on a constant basis (pharmacies, etc).

No additional software has been relied upon in the testing process to obtain results.

Test	Metric	Associated Criterion	Outcome	Challenges Encountered
Patient information can be accessed and edited on demand with appropriate permissions	Rate of Success	170.315 (b)(2)	100%	
Patient interventions can be accessed and edited on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100%	
Patient problems can be accessed and edited on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100%	
Patient medications can be accessed on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100%	
Patient allergies can be accessed on demand with appropriate permissions	Rate of Success	170.315(b)(2)	100%	
Confirmed presence of all required fields/data in patient transition of care documents	Rate of Success	170.315(b)(1)	100%	
System responds to all required prescription requests	Rate of Success	170.315(b)(3)	100%	
Exported CQMs contain all required fields	Rate of Success	170.315(c)(1)	100%	
CQMs can be exported on demand at any time with appropriate permissions	Rate of Success	170.315(c)(1)	100%	
Lab Reports can be downloaded in human readable format on demand by users with appropriate permissions	Rate of Success	170.315(e)(1)	100%	Where applicable - no challenges encountered, Lab Reports not present in every patient chart tested

Imaging Reports can be downloaded in human readable format on demand by users with appropriate permissions	Rate of Success	170.315(e)(1)	100%	Where applicable - no challenges encountered, Imaging Reports not present in every patient chart tested
Reports contain all required data	Rate of Success	170.315(e)(1)	100%	
Lab and Imaging Reports cannot be accessed by users without appropriate permissions	Rate of Success	170.315(e)(1)	100%	
Information can be accessed by a user with appropriate permissions via unique patient ID	Rate of Success	170.315(g)(7), 170.315(g)(9)	100%	
Download data on demand for single and multiple patients	Rate of Success	170.315(g)(10)	100%	

Key Milestones:

All Milestones are within the care setting of Cardiology Offices.

Milestone	Date/Timeframe
ACB approved RWT plans	January-Feb 15, 2024
Lille Group, Inc. wrote testing scripts	January 2024
Testing was performed	March 2024 - April 2024
Results were recorded and supplied to testing authority	April 2024
Results were assessed and compiled	May 2024 - July 2024
Report template was created	July 2024
Report was completed with results and evaluations	August 2024 - December 2024
Report submitted for ACB review	January 2025
Report revised per ACB feedback	January 2025
Report posted to Lille Group, Inc. website	February 1, 2025

Changes to Original Plan:

Testing was started later than originally indicated on the 2024 RWT plans. This was due to third party tester availability. There was no impact on testing due to the change in testing schedule, all testing was completed to plan within the time frame defined as acceptable in the RWT plans.

Results were compiled and assessed earlier than planned. Results were able to be compiled and assessed more quickly than anticipated by the testing authority. This had no impact on the results of testing. The report was created sooner than planned due to early testing results. This had no impact on the testing or result report. As per the RWT plan, all tests were completed at randomized times on randomized patients and were completed within the time frame set by ACB.

Evaluation of Results:

Real World Testing (RWT) for EscribeHOST was conducted by three testers familiar with the application in 2024. Explanation of the RWT process, instructions to third party testers on how to access the test environment as well as specific instructions on how to submit results were included in an introductory email and testers were asked to proceed on their own schedule using arbitrary times and dates, record time spent on each test and to alert the test administrator when complete. Results were compiled by the test administrator and saved for later review. These results were converted by the test administrator to rate of success in accordance with the RWT plans.

All third party testers were clear on expectations and testing time was well within established expectations set previously by internal testers, approximately 20 min per set of three patients per test for less than 1 hour of total testing time per testing session, excluding planned downtime per the RWT plan.

Testing results were clear and demonstrated each tester's facility with the EscribeHOST application as well as the application's functionality relative to generating desired results.

Results were expected in the 80-100% range for rate of success, and all results fell within this range. No tests were failed per the testing plan criteria, no modifications needed.

Testing successfully demonstrated real world usability on an on-going basis of EscribeHost in reference to all certified criteria.